NI200700312A - Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados. - Google Patents

Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados.

Info

Publication number
NI200700312A
NI200700312A NI200700312A NI200700312A NI200700312A NI 200700312 A NI200700312 A NI 200700312A NI 200700312 A NI200700312 A NI 200700312A NI 200700312 A NI200700312 A NI 200700312A NI 200700312 A NI200700312 A NI 200700312A
Authority
NI
Nicaragua
Prior art keywords
synthesis
alquilquinoleía
alquilquinazolina
kinasa
modulators
Prior art date
Application number
NI200700312A
Other languages
English (en)
Inventor
Baindur Nand
David Gaul Michael
Douglas Kreutter Kevin
Xu Guozhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NI200700312A publication Critical patent/NI200700312A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

.La invención se refiere a compuestos de alquilquinoleína y alquilquinazolina de fórmula C: en donde R1, R2, R99, y X son como se definen en el presente documento , el uso de tales compuestos en la síntesis de inhibidores de la proteína de tirosina cinasa, en particular inhibidores de FLT3 y/o c-kit y/o TrKB.
NI200700312A 2005-06-10 2007-11-29 Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados. NI200700312A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27
US78955106P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
NI200700312A true NI200700312A (es) 2009-02-19

Family

ID=37038264

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200700312A NI200700312A (es) 2005-06-10 2007-11-29 Intermediarios útiles en las síntesis de moduladores de la cinasa de alquilquinoleína y alquilquinazolina y métodos de síntesis relacionados.

Country Status (20)

Country Link
US (1) US7825244B2 (es)
EP (1) EP1891040A1 (es)
JP (1) JP2008545787A (es)
KR (1) KR20080033234A (es)
AR (1) AR054387A1 (es)
AU (1) AU2006258056A1 (es)
BR (1) BRPI0612543A2 (es)
CA (1) CA2611219A1 (es)
CR (1) CR9651A (es)
EA (1) EA200800010A1 (es)
EC (1) ECSP077993A (es)
GT (1) GT200600250A (es)
IL (1) IL187688A0 (es)
MX (1) MX2007015739A (es)
NI (1) NI200700312A (es)
NO (1) NO20080160L (es)
PA (1) PA8679201A1 (es)
TW (1) TW200718694A (es)
UY (1) UY29589A1 (es)
WO (1) WO2006135646A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8880138B2 (en) * 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
AU2014335312B9 (en) * 2013-10-16 2017-05-25 Fujifilm Corporation Salt of nitrogen-containing heterocyclic compound or crystal thereof, pharmaceutical composition, and FLT3 inhibitor
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
EP0822788B1 (en) 1995-04-19 2002-09-04 Schneider (Usa) Inc. Drug release coated stent
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
JP2001511764A (ja) 1996-04-12 2001-08-14 住友製薬株式会社 ピペリジニルピリミジン誘導体
ATE480521T1 (de) 1996-10-01 2010-09-15 Kyowa Hakko Kirin Co Ltd Stickstoff enthaltende heterocyclische verbindungen
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
EP1309569B1 (en) 2000-08-18 2010-10-06 Millennium Pharmaceuticals, Inc. N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors
AU2001293207A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
CA2424689A1 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
ATE310004T1 (de) 2000-12-12 2005-12-15 Neurogen Corp Spiro(isobenzofuran-1,4'-piperidin)-3-one und 3h- spiroisobenzofuran-1,4'-piperidine
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
ES2310202T3 (es) * 2001-04-26 2009-01-01 EISAI R&D MANAGEMENT CO., LTD. Compuesto ciclico condensado que contiene nitrogeno que tiene un grupo pirazolilo como grupo sustituyente y composicion farmaceutica del mismo.
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
TWI302836B (en) 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP2005537247A (ja) 2002-06-27 2005-12-08 シエーリング アクチエンゲゼルシャフト 置換されたキノリンｃｃｒ５受容体アンタゴニスト
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
CA2495386C (en) 2002-08-14 2011-06-21 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
SI1678166T1 (sl) 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) * 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators

Also Published As

Publication number Publication date
GT200600250A (es) 2007-03-14
PA8679201A1 (es) 2007-01-17
UY29589A1 (es) 2006-10-02
WO2006135646A1 (en) 2006-12-21
AU2006258056A1 (en) 2006-12-21
US7825244B2 (en) 2010-11-02
NO20080160L (no) 2008-01-09
TW200718694A (en) 2007-05-16
JP2008545787A (ja) 2008-12-18
EP1891040A1 (en) 2008-02-27
CR9651A (es) 2008-09-09
CA2611219A1 (en) 2006-12-21
MX2007015739A (es) 2008-04-29
AR054387A1 (es) 2007-06-20
IL187688A0 (en) 2008-08-07
BRPI0612543A2 (pt) 2010-11-23
EA200800010A1 (ru) 2008-06-30
KR20080033234A (ko) 2008-04-16
ECSP077993A (es) 2008-01-23
US20070021436A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
GT200600143A (es) Fenilacetamidas apropiadas como inhibidores de la proteina kinasa
CR9652A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
CR10072A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
ATE512151T1 (de) Pyrrolotriazin-kinaseinhibitoren
CR9591A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
EA200870116A1 (ru) Бициклические гетероарильные соединения
CR11861A (es) Compuestos organicos
CY1113642T1 (el) Γεφυρωμενες δικυκλικες ετεροαρυλ υποκατεστημενες τριαζολες, χρησιμες ως αναστολεις της axl
NI200700313A (es) Aminopirimidinas como moduladores de la cinasa .
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
GT200600181A (es) Derivados de amida sustituida y metodos de uso
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
GT200500238A (es) Fenilaminotiazoles sustituidos y su uso
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
EA200800701A1 (ru) 4-замещенные пирролидин-2-оны и их применение
NI200700316A (es) Aminopirimidinas como moduladores de la cinasa
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
DE602006009789D1 (de) Acetylenderivate
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
UY29040A1 (es) Procedimiento de amino-tropano, su preparación y aplicación en terapéutica